Stock market analyst Rajesh Gupta of Fairwealth Securities has maintained 'buy' rating on J B Chemicals & Pharmaceuticals Ltd stock with target between Rs 107-109.

According to analyst, the interested investors can buy the stock around Rs 103.85 with stop loss of Rs 102.

The stock of the company, on August 16, closed at Rs 102.25 on the Bombay Stock Exchange (BSE).

Current EPS & P/E ratio stood at 12.84 and 7.99 respectively.

The share price has seen a 52-week high of Rs 106.60 and a low of Rs 45.90 on BSE.

During the quarter ended June 30, the company's announced a phenomenal growth in its standalone net profit, which grew by 57.62%.

The company's net profit during the period stood at Rs 206.94 million as against Rs 131.29 million during the corresponding period of 2009.

J B Chemicals & Pharmaceuticals Ltd said that its net sales during the period under review surged 17.52% to Rs 1,588.70 million from the same period of last year.

The company's total income for the three month period ended June 30 zoomed 18.17% to Rs 1,598.04 million.

The EPS of the company for the quarter stood at Rs 2.45 per share, up 57.05% as against the same period of 2009.

During FY'10, J B Chemicals successfully rolled out 'Unispaz' (OTC) in the Russian market and 3 more new products are set to launch during the existing year.

Moreover, the company has also decided to introduce novel products at regular interval with the aim to back up its development policies.